喷昔洛韦
泛昔洛韦
药代动力学
最大值
医学
药理学
交叉研究
加药
伐昔洛韦
生物等效性
尿
口服
不利影响
内科学
病毒学
病理
单纯疱疹病毒
安慰剂
疱疹病毒科
病毒性疾病
病毒
替代医学
作者
M. A. Pue,Sue Pratt,Amanda J. Fairless,Susan Fowles,Julian Laroche,Panayiotis G. Georgiou,William Prince
摘要
Twenty healthy male volunteers received single oral doses of famciclovir (125–750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma concentrations of penciclovir were obtained at median times of 0.5–0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (Cmax) increased linearly with dose of famciclovir. Time to Cmax, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects with a low incidence of adverse effects. In conclusion, penciclovir thus displays linear pharmacokinetics in the anticipated therapeutic dose range of famciclovir.
科研通智能强力驱动
Strongly Powered by AbleSci AI